Skip to main content

Advertisement

Table 2 Incidence (per 100 person-years) of outcomes among the ACEi and ARB users after propensity score weighting

From: A comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse cardiovascular events in diabetic patients: a population-based dynamic cohort study in Taiwan

  Incidence (95 % CI) Hazard ratio (95 % CI)
ACEi (n = 6898) ARB (n = 12,758) ACEi vs. ARB P value
MACE
 Any MACEa 9.33 (8.90−9.76) 9.62 (9.16−10.08) 1.03 (0.96−1.10) 0.4244
 Cogestive heart failure 1.48 (1.33−1.63) 1.51 (1.35−1.67) 1.06 (0.91−1.22) 0.4538
 Stroke 3.78 (3.53−4.03) 3.56 (3.31−3.82) 1.12 (1.02−1.24) 0.0230
 Malignant dysrhythmia 0.16 (0.12−0.21) 0.15 (0.10−0.20) 1.14 (0.73−1.77) 0.5571
 Cardiogenic shock 0.03 (0.01−0.06) 0.04 (0.02−0.07) 0.81 (0.31−2.07) 0.6547
 MI or PCI 1.77 (1.61−1.93) 2.19 (2.00−2.39) 0.89 (0.78−1.01) 0.0646
 CABG 0.18 (0.13−0.23) 0.22 (0.16−0.28) 0.89 (0.60−1.31) 0.5438
 Thrombolysis therapy 0.00 (0.00−0.02) 0.02 (0.01−0.05) 0.19 (0.02−1.66) 0.1339
 ESRD 0.44 (0.36−0.52) 0.63 (0.53−0.73) 0.69 (0.54−0.88) 0.0025
  1. ACEi angiotensin converting enzyme inhibitors, ARB angiotensin receptor blockers, CI confidence interval, MACE major adverse cardiovascular disease, MI myocardial infarction, CHF cogestive heart failure, PCI percutaneous coronary intevention, CABG coronary artery bypass graft surgery, ESRD end stage renal disease
  2. aMACE = CHF or stroke or malignant dysrhythmia or cardiogenic shock or MI or PCI or CABG or thrombolysis therapy